免疫实践咨询委员会关于COVID-19疫苗额外基础剂量和加强剂量的临时建议——美国,2021年
美国免疫实践咨询委员会(ACIP)针对FDA修订紧急使用授权后,发布COVID-19疫苗额外基础剂量和加强剂量的临时建议。额外基础剂量指对可能未产生保护性免疫应答者接种的剂量,加强剂量指为增强或恢复随时间可能减弱保护力而接种的剂量。医务人员在基础、额外和加强接种中发挥关键作用。
要点
- 额外基础剂量针对可能未对初始接种产生保护性免疫应答者。
- 加强剂量用于增强或恢复随时间可能减弱的基础免疫保护。
- 医务人员在COVID-19基础、额外和加强接种中发挥关键作用。
核心结论
- ACIP针对FDA修订紧急使用授权后,发布COVID-19疫苗额外基础剂量和加强剂量的临时建议。
- 额外基础剂量指对可能未对初始接种产生保护性免疫应答者接种的疫苗剂量。
- 加强剂量指为增强或恢复随时间可能减弱的基础免疫保护而接种的疫苗剂量。
研究设计与样本
- 美国免疫实践咨询委员会(ACIP)制定的临时建议,基于FDA对COVID-19疫苗紧急使用授权的修订。
主要发现
- 2021年8月,FDA修订两种mRNA COVID-19疫苗的紧急使用授权,允许某些免疫功能受损的初始mRNA COVID-19疫苗系列接种者接种额外基础剂量。
- 2021年9月至10月,FDA修订紧急使用授权,允许某些年龄≥18岁、COVID-19严重并发症风险增加或暴露于SARS-CoV-2的初始mRNA COVID-19疫苗系列接种者接种加强剂量,以及年龄≥18岁的Janssen COVID-19疫苗接种者接种加强剂量。
关键数值与推荐
- FDA批准生物制品许可申请或授权紧急使用并由ACIP推荐基础接种的COVID-19疫苗包括:2剂mRNA基础辉瑞-BioNTech/Comirnaty和Moderna COVID-19疫苗,以及单剂腺病毒载体Janssen(强生)COVID-19疫苗。
- 2021年8月,FDA修订两种mRNA COVID-19疫苗的紧急使用授权,允许某些免疫功能受损的初始mRNA COVID-19疫苗系列接种者接种额外基础剂量。
- 2021年9月至10月,FDA修订紧急使用授权,允许某些年龄≥18岁、COVID-19严重并发症风险增加或暴露于SARS-CoV-2的初始mRNA COVID-19疫苗系列接种者接种加强剂量。
- 2021年9月至10月,FDA修订紧急使用授权,允许年龄≥18岁的Janssen COVID-19疫苗接种者接种加强剂量。
临床怎么用
- 医务人员在COVID-19疫苗接种工作中发挥关键作用,包括基础、额外和加强接种,尤其保护重症和死亡风险增加的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Three COVID-19 vaccines are currently approved under a Biologics License Application (BLA) or authorized under an Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) and recommended for primary vaccination by the Advisory Committee on Immunization Practices (ACIP) in the United States: the 2-dose mRNA-based Pfizer-BioNTech/Comirnaty and Moderna COVID-19 vaccines and the single-dose adenovirus vector-based Janssen (Johnson & Johnson) COVID-19 vaccine (1,2) (Box 1). In August 2021, FDA amended the EUAs for the two mRNA COVID-19 vaccines to allow for an additional primary dose in certain immunocompromised recipients of an initial mRNA COVID-19 vaccination series (1). During September-October 2021, FDA amended the EUAs to allow for a COVID-19 vaccine booster dose following a primary mRNA COVID-19 vaccination series in certain recipients aged ≥18 years who are at increased risk for serious complications of COVID-19 or exposure to SARS-CoV-2 (the virus that causes COVID-19), as well as in recipients aged ≥18 years of Janssen COVID-19 vaccine (1) (Table). For the purposes of these recommendations, an additional primary (hereafter additional) dose refers to a dose of vaccine administered to persons who likely did not mount a protective immune response after initial vaccination. A booster dose refers to a dose of vaccine administered to enhance or restore protection by the primary vaccination, which might have waned over time. Health care professionals play a critical role in COVID-19 vaccination efforts, including for primary, additional, and booster vaccination, particularly to protect patients who are at increased risk for severe illness and death.
引用
- Mbaeyi S, Oliver SE, Collins JP, et al. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34735422. doi:10.15585/mmwr.mm7044e2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。